Company intelligence
Imagion Biosystems, Inc
Transforming Medical Imaging to Save Lives
About Imagion Biosystems, Inc
Imagion Biosystems is advancing a new era of cancer detection through our proprietary MagSense® technology. MagSense® combines bio-safe magnetic nanoparticles with molecular targeting to detect cancer cells with high specificity—bringing molecular-level precision to MRI. By enhancing imaging accuracy without ionizing radiation, we aim to reduce unnecessary procedures and support earlier, more confident diagnosis. Our work sits at the intersection of nanotechnology, medical imaging, and oncology. Focused initially on breast and prostate cancers, MagSense® is designed to seamlessly integrate with existing MRI infrastructure, creating a scalable solution with global potential. With a multidisciplinary team and strong scientific foundation, we are committed to developing non-invasive, next-generation diagnostics that improve outcomes and transform the way cancer is found and managed.
Verified activity
Signals from Imagion Biosystems, Inc
2 published signals
Presence & Recognition
Imagion Biosystems, Inc. released an updated investor presentation reflecting FDA clearance of its IND in June and near-term activities for the MagSense HER2 Phase 2 trial.
Reported by Imagion Biosystems, Inc
Presence & Recognition
Imagion Biosystems, Inc. Executive Chairman Bob Proulx attended a discussion on the lead up to the U.S. clinical study at The Stock Network.
Reported by Imagion Biosystems, Inc